130 related articles for article (PubMed ID: 20553208)
1. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Bellmunt J; Fishman M; Eisen T; Quinn D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
[TBL] [Abstract][Full Text] [Related]
2. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
4. Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Procopio G
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1689-92. PubMed ID: 22050017
[TBL] [Abstract][Full Text] [Related]
5. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
[TBL] [Abstract][Full Text] [Related]
6. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
7. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
8. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M
Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Takeuchi A; Eto M; Tatsugami K; Yamada H; Oki T; Kiyoshima K; Yoshikai Y; Naito S
J Urol; 2010 Dec; 184(6):2549-56. PubMed ID: 21030044
[TBL] [Abstract][Full Text] [Related]
12. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Sciarra A; Autran Gomez AM; Gentilucci A; Parente U; Salciccia S; Gentile V; Di Silverio F
Eur Urol; 2007 Aug; 52(2):597-9. PubMed ID: 17420088
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
16. Molecule of the month. Sorafenib.
Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
[No Abstract] [Full Text] [Related]
17. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
18. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
